Advances and Controversies in the Biology and Therapy of Acute Leukemia and Myelodysplasia

Friday, April 21, 2017 – San Francisco, CA

7:00–7:40  Registration and Breakfast

7:45–7:50  Introduction
            Jacob M. Rowe, Co-Chairman

Session 1: Basic Biology
Moderators: Marshall A. Lichtman, MD
            Sean Morrison, PhD

7:50–8:05  Mutational complexity in myelodysplasia
            R. Coleman Lindsley, MD, PhD

8:05–8:15  Discussion

8:15–8:30  Maintenance of telomere length in AML
            Peter M. Lansdorp, MD, PhD

8:30–8:40  Discussion

8:40–8:55  Familial AML
            Jane E. Churpek, MD

8:55–9:05  Discussion

9:05–9:25  Break

Session 2: Induction and Post-Remission Therapy
Moderators: Elihu H. Estey, MD
            Harry Erba, MD, PhD

9:30–9:45  Have genomics superseded IPSS as the best prognostic index for myelodysplasia?
            David Steensma, MD

9:45–9:55  Discussion

9:55–10:10 How can one optimize induction therapy in AML?
            Selina Luger, MD

10:10–10:20 Discussion
### Session 3: Bone Marrow Transplantation

**Moderators:** Daniel J. Weisdorf, MD  
Robert J. Soiffer, MD

**10:20–10:35**  
*Is there a role for bispecific antibodies in AML?*  
*John Dipersio, MD, PhD*

**10:35–10:45**  
Discussion

**11:00–11:10**  
**Does cytogenetics affect the post-remission strategy for older patients with AML in CR1?**  
*James M. Foran, MD*

**11:25–11:35**  
Discussion

**10:45–11:00**  
**Which novel therapies are likely to be incorporated into frontline therapy of AML?**  
*Richard M. Stone, MD*

**11:00–11:10**  
Discussion

**11:35–12:35**  
**Lunch**

**Session 3: Bone Marrow Transplantation**

**12:40–12:55**  
**Relapsed ALL: Is it crucial to achieve molecular remission prior to transplant?**  
*Mary Eapen, MD*

**12:55–1:05**  
Discussion

**1:05–1:20**  
**Have allogeneic transplants made a significant impact on the outcome of older patients with AML?**  
*Frederick R. Appelbaum, MD*

**1:20–1:30**  
Discussion

**1:30–1:45**  
**Is it time to revisit autologous transplants for AML?**  
*Hillard M. Lazarus, MD*

**1:45–1:55**  
Discussion

**1:55–2:10**  
**Which factors influence the development of GvHD in HLA-matched or mismatched transplants?**  
*Effie W. Petersdorf, MD*

**2:10–2:20**  
Discussion
2:20–2:40  Break

**Session 4: Supportive Care and Perspective**

**Moderators:** Kenneth Kaushansky, MD  
Nancy Berliner, MD

2:45–3:00  Cytokine release syndrome: Who is at greatest risk and how to treat?  
*Noelle Frey, MD, MS*

3:00–3:10  Discussion

**Ernest Beutler Memorial Lecture**

3:10–3:20  Introduction of Aaron Ciechanover, MD, DSc  
*Jacob M. Rowe, MD, Co-Chairman*

3:20–3:50  Ubiquitins in Cancer  
*Aaron Ciechanover, MD, DSc*

3:50–3:55  Discussion

3:55–4:00  Concluding Remarks and Close  
*Martin S. Tallman, MD, Co-Chairman*